Follow The Filings

OLMA Olema Pharmaceuticals Inc.

Health Care, filed as Olema Pharmaceuticals Inc (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

  • 1 Owner
  • Max 0.2%
  • $12M

Who owns this now

Largest portfolio weights among holders, up to 0.2% (Stanley Druckenmiller, Duquesne Family Office). Not free-float ownership.

  1. Stanley Druckenmiller 0.24%

Who owns OLMA

Sorted by value, long equity only, as of 2026 Q2.

History
Stanley Druckenmiller, Duquesne Family Office 0.24% Hold 986,827 $12M History

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by OLMA's executives, directors and 10% owners in the last 12 months, from their Form 4s

All OLMA insider trades
  • None no insider bought on the open market
  • $24.7M sold by 6 insiders outside a trading plan
  • None no planned (10b5-1) sales
  1. Cyrus Harmon Director
    Sale
    $291K 25,000 shares at $11.65 3.4% of stake
    Traded Jul 23–24 Filed Jul 27
  2. Shawnte Mitchell Chief Legal Officer
    Sale
    $952K 40,000 shares at $23.79
    Traded Mar 3–4 Filed Mar 5
  3. Cyrus Harmon Director
    Sale
    $269K 10,000 shares at $26.88 1.4% of stake
    Traded Jan 20 Filed Jan 21
  4. Cyrus Harmon Director
    Sale
    $102K 3,489 shares at $29.12 0.5% of stake
    Traded Jan 14 Filed Jan 16
  5. Shane William Charles Kovacs Ch. Operating & Financial Off.
    Sale
    $3M 103,822 shares at $28.70 43% of stake
    Traded Jan 13–15 Filed Jan 15
  6. David C. Myles Ch. Discov. & Non-clin Dev Off
    Sale
    $3.1M 110,000 shares at $28.25
    Traded Jan 12–14 Filed Jan 14
  7. Cyrus Harmon Director
    Sale
    $82K 2,881 shares at $28.53 0.4% of stake
    Traded Dec 22, 2025 Filed Dec 29, 2025
  8. Naseem Zojwalla Chief Medical Officer
    Sale
    $7.5M 269,509 shares at $27.94 98% of stake
    Traded Dec 19–23 Filed Dec 23, 2025
  9. David C. Myles Ch. Discov. & Non-clin Dev Off
    Sale
    $1.6M 51,000 shares at $30.46 8.5% of stake
    Traded Dec 19, 2025 Filed Dec 23, 2025
  10. Ian T Clark Director
    Sale
    $7.9M 264,800 shares at $29.73 100% of stake
    Traded Dec 19, 2025 Filed Dec 23, 2025

Also filed in the last 12 months, not counted as buying or selling: 13 option exercises, 5 gifts, and 1 stock grant.

SEC filings

Recent issuer filings from EDGAR, 24 shown.

Filed Form Detail Links
SCHEDULE 13D/A —
8-K 5.02
8-K 5.02,7.01,9.01
8-K 2.02,9.01
10-Q
SCHEDULE 13G/A —
SCHEDULE 13G/A —
8-K 5.07
8-K 7.01,8.01,9.01
8-K 7.01,8.01,9.01
SCHEDULE 13G/A —
SCHEDULE 13G/A —
8-K 2.02,9.01
10-Q
8-K 1.01,2.03
DEF 14A
8-K 5.02,7.01,9.01
DEFA14A
SCHEDULE 13G —
8-K 2.02,9.01
10-K
SCHEDULE 13G/A —
SCHEDULE 13G/A —
SCHEDULE 13G/A —

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Net income -$96.66M -$129.47M -$162.45M

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $266.51M $438.47M $515.45M
Total non-current assets * $10.43M $12.51M $17.98M
Total assets $276.94M $450.98M $533.43M
Total current liabilities $21.62M $41.76M $51.8M
Total non-current liabilities * $1.43M $0.257M $3.07M
Total equity $253.9M $408.96M $478.56M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$83.73M -$104.35M -$146.72M
Cash from investing -$4.85M -$93.53M -$155.76M
Cash from financing $133.42M $268.82M $211.3M
Net change in cash $44.84M $70.94M -$91.18M

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.